EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone

Mark Ellison, Emily Hutton, Lynn Webster, Phil Skolnick iD

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.2421 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Mark Ellison und 3 weiteren Autor:innen. Beteiligte Einrichtung: Phax Pharma, Watford, UK. Hauptthemen laut MEDLINE: Naloxone, Administration, Intranasal, Naltrexone, Respiratory Insufficiency. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An open‐label, randomized, crossover study in healthy volunteers compared the reversal of remifentanil‐induced respiratory depression by intranasal (IN) naloxone hydrochloride (4 mg) to IN nalmefene (2.7 mg) (NCT 04828005). Subjects were administered a hypercapnic gas mixture which produces an elevation in minute ventilation (MV), a result of the ventilatory response to hypercapnia. Subjects breathed a hypercapnic gas mixture through a tight‐fitting mask for an initial period of 46 min prior to a series of mask “holidays” introduced to reduce subject discomfort and encourage study completion. Ten minutes after initiating the hypercapnic gas mixture, a remifentanil bolus was administered, and an infusion continued for the study duration. Subjects were administered either naloxone or nalmefene 15 min after initiating the remifentanil infusion and MV monitored for 21 min followed by a mask holiday. Both nalmefene and naloxone produced a time‐dependent reversal of remifentanil‐induced reductions in MV measured 2.5–20 min post administration. At the primary endpoint (5 min post administration), nalmefene increases in MV (5.75 L/min) were nearly twice that produced by naloxone (3.01 L/min) ( P < .0009); the point estimate favors nalmefene, demonstrating non‐inferiority and superiority. In this model of opioid‐induced respiratory depression, nalmefene has a more rapid onset of action than naloxone, which required 20 min to achieve a comparable reversal of respiratory depression. Both nalmefene and naloxone were well tolerated by healthy volunteers. This rapid onset of action may prove particularly valuable in an era when over 90% of fatalities are linked to synthetic opioid overdose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaloxoneAdministration, IntranasalNaltrexoneRespiratory InsufficiencyCross-Over StudiesAnalgesics, OpioidNarcotic AntagonistsRemifentanilHealthy VolunteersHumansMaleAdultFemaleYoung AdultMiddle Aged

Stichwörter der Autor:innen

minute ventilation‐opioid overdosenalmefenenaloxoneremifentanilrespiratory depression

Substanzen

NaloxonenalmefeneNaltrexoneAnalgesics, OpioidNarcotic AntagonistsRemifentanil

Autor:innen und Institutionen

  • Phax Pharma, Watford, UK.
  • Indivior, Inc., N, Chesterfield, VA, USA.
  • Dr. Vince Clinical Research, Overland Park, KS, USA.
  • Center for U.S. Policy, Washington, DC, USA.

ORCID-Profile: Phil Skolnick

Zitieren

APA

Ellison, M., Hutton, E., Webster, L., & Skolnick, P. (2024). Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2421

Vancouver

Ellison M, Hutton E, Webster L, Skolnick P. Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2421

BibTeX
@article{Ellison2024,
  author = {Ellison, Mark and Hutton, Emily and Webster, Lynn and Skolnick, Phil},
  title = {Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.2421}
}
Kostenlos starten →